Thursday May 6, 2010

8:30-10:45 PLENARY SESSION I (HALL A)
Chairs: C. Cooper, E. Lau

  • Plenary Lecture 1 - Cellular Control of Bone Mass - R. Baron (US)
  • ESCEO-Amgen Fellowships Award Ceremony
  • Plenary Lecture 2 - Osteoporosis, Hip Fracture and the Biology of Aging -
    S. R. Cummings (US)
  • Oral Communications (5)

10:45-11:05
Break

11:05-12:05
Meet-the-Expert Sessions

  • Practical Approach of Glucocorticoid-treated Patients - J. Adachi (CA)
  • Bone Disease in Primary Hyperparathyroidism - J.P. Bilezikian (US)
  • BMU Balance: Effects of Antiosteoporotic Agents - J. Compston (UK)
  • Epidemiological Aspects of Osteoporosis - C. Cooper (UK)
  • Optimal Dose of Vitamin D - B. Dawson-Hughes (US)
  • Assessing Bone Strength Beyond DXA - C. C. Glüer (DE)
  • Fracture Healing: Can We Influence It? - J. Goldhahn (CH)
  • Bisphosphonates in Chronic Renal Failure - S. E. Papapoulos (NL)
  • Health Economics and Treatment Selection - J.Y. Reginster & O. Bruyère (BE)
  • Osteoporosis in Men - E. Seeman (AU)

11:05-12:05
ESCEO-FROMO Session: Dermatological Side Effects of Antiosteoporosis Medications (ROOM 11)
Chairs: D. Felsenberg, R. Rizzoli

  • Introduction - J.Y. Reginster (BE)
  • Various aspects of drug-related dermatological lesions - P. Musette (FR)
  • Cutaneous side effects of antiosteoporosis treatments - P. Musette (FR)
  • Discussion - All Faculty (Moderator D. Felsenberg)
  • Conclusions - R. Rizzoli (CH)

12:05-12:15
Break

12:15-13:45
Lunch Satellite Symposium - SERVIER
Superior Antifracture Efficacy From Improved Bone Quality (HALL A)

12:15-13:45
Lunch Satellite Symposium - MEDTRONIC
Optimising Patient Care in Osteoporotic Vertebral Compression Fractures: The Role of Minimally Invasive Therapies (HALL B)

13:45-14:30 Poster Session 1

14:30-15:30
Meet-the-Expert Sessions

  • Side Effects of Anti Fracture Drugs - S. Adami (IT)
  • Post-fracture Management - K. Akesson (SE)
  • Vertebro/kyphoplasty - S. Boonen (BE)
  • Pharmacogenomics - M.L. Brandi (IT)
  • BMU Balance: Effects of Antiosteoporotic Agents - J. Compston (UK)
  • Issues in Designing and Conducting Clinical Trials - S. R. Cummings (US)
  • Muscle and Bone Interaction - D. Felsenberg (DE)
  • Genetics and Osteoporosis: How to Assess it? - S. Ferrari (CH)
  • Premenopausal Osteoporosis - U. Liberman (IL)
  • Gait and Falls - T. Masud (UK)

14:30-15:30
IOF Mini-symposium - Growth and Development of the Skeleton (ROOM 11)
Chairs: R. Lorenc, R. Rizzoli

  • Fetal and Neonatal Determinants of Bone Mineral Accumulation - C. Cooper (UK)
  • Novel Findings in Bone Development - E. Seeman (AU)
  • Coeliac Disease and Peak Bone Mass - M.L. Bianchi (IT)

15:30-15:45
Break

15:45-17:45 PLENARY SESSION II (HALL A)
Chairs: R. Lederman, E.V. McCloskey

  • Plenary Lecture 3 - Why do Bones Break? Contributions of Cortical and Trabecular Bone - M. L. Bouxsein (US)
  • Plenary Lecture 4 - OLOF JOHNELL MEMORIAL LECTURE:
    Do Men and Women Fracture at the Same BMD?     - J.A. Kanis (UK)
  • Oral Communications (5)

17:45-18:15
Break

18:15-19:45
Satellite Symposium - NOVARTIS
Zoledronic Acid 5 mg – Optimizing Fracture Protection in Osteoporosis Treatment (HALL A)

18:15-19:45
Satellite Symposium - ELI LILLY
Strategies and Tactics For the Management of Severe Osteoporosis (HALL B)